Skin cancers, including malignant melanoma, keratinocyte cancer (formerly non- melanoma skin cancer) and also more rare skin cancers are increasing rapidly in most fair-skinned populations. A skin cancer diagnosis has impact not only on health economics but also on the quality of life of the individual. In our research group we focus on clinical skin cancer research as well as on translational skin cancer research and registry-based skin cancer research. Our research spans from diagnostic methods, dermato-oncologic surgery, imaging and artificial intelligence in dermatology to prognostic biomarkers.
The specific aims of our research are to identify risk factors and prognostic factors associated with certain skin cancer diagnoses, as malignant melanoma, basal cell carcinoma and cutaneous squamous cell carcinoma. We also strive to identify factors that can optimize the care of patients with a skin cancer diagnosis, both before the diagnosis and after the diagnosis. We co-operate with research units that perform imaging, genomics, proteomics and conventional histopathology.
Within the BioMEL project, we collaborate with LUCC (Lund University Cancer Center) and many of the clinical units that perform metastatic surgery and treatment for disseminated malignant melanoma. One aim is that our imaging and biomarker research on primary melanoma in the future can help to reflect biological aggression, metastatic potential and predict treatment response in a specific melanoma tumor.